The Gene That Turns Standard Chemotherapy Into Poison — and the Test That Prevents It

A common chemo drug is safe for most people and lethal for a few — and a single genetic test tells the two apart before the first dose.

There is a chemotherapy drug given to hundreds of thousands of cancer patients every year that is safe and effective for most people — and life-threatening for a few. The difference between the two groups is often a single gene: DPYD. A simple test before treatment can tell them apart, and regulators now recommend it.

The drugs in question

Fluoropyrimidines — 5-fluorouracil (5-FU) and its oral cousin capecitabine (Xeloda) — are cornerstone chemotherapy drugs used to treat colorectal, breast, gastric, head-and-neck and other common cancers. They've been part of standard cancer care for decades. For most patients, the side effects are the familiar, manageable ones of chemotherapy.

But for a subset of patients, the same standard dose triggers severe, sometimes fatal toxicity — devastating damage to the gut lining, blood cells and other rapidly dividing tissues, appearing early and escalating fast.

Why the same drug is safe for some and deadly for others

The body relies on an enzyme called dihydropyrimidine dehydrogenase (DPD) to break down and inactivate the large majority of a fluoropyrimidine dose. The DPYD gene codes for that enzyme. If you carry certain DPYD variants, your DPD enzyme is partially or completely deficient — so the drug isn't cleared properly and accumulates to toxic levels. A "standard" dose becomes, in effect, a massive overdose.

Regulators and guidelines now recommend pre-treatment testing

This isn't fringe or speculative — it's mainstream, endorsed practice:

• European regulators (EMA) and UK bodies (MHRA/NHS) have recommended DPD-deficiency testing before starting these drugs, and NHS England commissions DPYD testing nationally.
• The FDA updated the safety labeling for capecitabine and fluorouracil to warn about DPD deficiency and to advise testing for DPYD variants before treatment (unless immediate treatment is necessary), reflecting the seriousness of the risk.
• Clinical pharmacogenomics guidelines (CPIC) provide an activity-score system that translates a patient's DPYD genotype into a recommended dose adjustment — or, for complete deficiency, avoiding the drug entirely.

What genotype-guided dosing does

When a DPYD variant is found before treatment, the response isn't necessarily to abandon chemotherapy — it's to adjust the dose to match the patient's reduced enzyme capacity, or to choose a different regimen. Studies show that genotype-guided dosing in carriers substantially reduces severe toxicity and hospitalizations. Patients still get treated for their cancer; they just get treated safely.

The honest limitations

DPYD testing isn't a perfect shield. The variants most commonly tested predict a meaningful share of severe early toxicities, but not all of them — someone can still have a bad reaction despite a "normal" DPYD result, since toxicity has other causes too. Much of the evidence comes from European-ancestry populations, and the known variants may not capture risk equally across all ancestries. So a normal test reduces but doesn't eliminate risk, and vigilance during treatment remains essential.

Why you might want to know in advance

Cancer treatment often begins under time pressure. Having your DPYD status already sequenced — as part of a whole genome done earlier — means the information is available immediately if you're ever prescribed a fluoropyrimidine, without waiting on a separate test. If you or a family member is facing chemotherapy with 5-FU or capecitabine, DPYD testing is a reasonable, evidence-backed thing to ask your oncologist about.

This article is for general educational purposes only and is not medical advice. Genetic results should be interpreted with a qualified healthcare provider or genetic counselor. Do not start, stop, or change any medication or treatment based on this article.